Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450405 · ClinicalTrials.gov registry record · Phase 4
Androgen Effects on the Reproductive Neuroendocrine Axis
A Phase 4 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT06450405: Clinical Trial Phase 4 study, sponsored by University of California, San Diego.
NCT06450405 is a Phase 4 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06450405, a Phase 4 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
Primary Outcome
Evidence of Luteal Activity (ELA), as defined by serum progesterone level above 3 ng/mL in transgender men initiating testosterone replacement therapy.
Interventions
- DRUG Testosterone Cypionate 50 MG/ML Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 4 |
Why NCT06450405 stopped before completion
NCT06450405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Testosterone Cypionate 50 MG/ML Injectable Solution is the first listed.
NCT06450405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06450405 about?
NCT06450405 is a clinical study titled "Androgen Effects on the Reproductive Neuroendocrine Axis". This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
What is the current status of trial NCT06450405?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2025-02-26. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT06450405?
The interventions under investigation include: Testosterone Cypionate 50 MG/ML Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT06450405?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06450405's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI